BioReliance Introduces New Predictive Assays

BioReliance announced on Oct. 16, 2014 that it is adding toxicology and in-vitro ADME (absorption, distribution, metabolism, and excretion) testing services to its suite of offerings. The testing service will help customers predict the levels of permeability, transport, metabolism, and toxicity in drug product in early discovery phases. With the help of this technology, customers will be able to isolate potential compounds that may affect the safety or efficacy of a drug product in development.

The assays use genetically modified cell lines made with CompoZr zinc finger nuclease, which is a Sigma-Aldrich proprietary technology. BioReliance is a Sigma-Aldrich company under SAFC Commercial.

“A shift in emphasis to testing in earlier phases of drug discovery and development, increasing efforts to reduce cost, stricter regulatory guidance, and a reduction in animal usage is driving the demand for more predictive in-vitro ADME and tox assays and services,” said Paul Brooks, PhD, head of discovery research services at Sigma-Aldrich in a press release. “Our expanding portfolio of cell lines, available as products and now services, is creating the most comprehensive and accessible platform for in-vitro ADME and toxicology testing in the market.”